Gliclazide

Its chemical name is: l_(3-azabicyclo【3.3.0】octyl)-3-p-toluenesulfonylurea.

1 The following drugs may increase the risk of hypoglycemia. (1) Concomitant use is prohibited: Miconazole (oral route, oral gel): Increases the hypoglycemic effect and may cause hypoglycemic symptoms, even coma. (2) Concomitant use is not recommended: ① Phenylbutazone (systemic route): Increases the hypoglycemic effect of sulfonylurea drugs [replaces their binding to plasma proteins and (or) reduces their clearance]. It is best to use an anti-inflammatory drug with few interactions. Otherwise, the patient should be warned and the importance of self-monitoring should be emphasized; when used with anti-inflammatory drugs, it is necessary to adjust the drug dosage during treatment and during the treatment interruption stage. ② Alcohol: Increases hypoglycemic reactions, especially chlorpropamide, glibenclamide, glipizide, and toluidine (by inhibiting compensatory reactions), and also increases the risk of hypoglycemic coma. Avoid consuming alcohol or taking medications containing alcohol. (3) Caution is required in combined use: ① SZL receptor blockers: All SZL receptor blockers can mask certain symptoms of hypoglycemia, such as palpitations and tachycardia. Most non-cardioselective szlig; receptor blockers increase the suddenness and severity of hypoglycemia. Patients should be warned and the importance of self-monitoring of blood glucose should be emphasized, especially at the beginning of treatment. ② Fluconazole: Increases the half-life of sulfonylurea drugs and the risk of hypoglycemia symptoms. Patients should be warned and the importance of self-monitoring of blood glucose should be emphasized, and the dose of sulfonylurea drugs should be adjusted when necessary during fluconazole treatment. ④ Angiotensin-converting enzyme inhibitors (generally referring to captopril and enalapril): The use of angiotensin-converting enzyme inhibitors will aggravate the hypoglycemic effect of sulfonylurea hypoglycemic drugs. Symptomatic hypoglycemia is very rare. One theory is that improved glucose tolerance helps reduce the need for insulin. The importance of self-monitoring of blood glucose should be emphasized. 2 The following drugs may cause increased blood sugar levels: (1) It is recommended not to use them in combination: ① Danazol: Diabetogenic effect. If this drug cannot be avoided, patients should be warned and the importance of self-monitoring of urine sugar and blood sugar should be emphasized. When using and stopping ILdanazol treatment, the dose of diabetes treatment drugs needs to be adjusted. (2) Combined use requires caution: ① Chlorpromazine (psychotropic agent): Treatment with high-dose chlorpromazine (daily chlorpromazine dose of 100 mg) will increase blood sugar levels (reduce insulin release). Inform patients and emphasize the need for self-monitoring of IIL glucose levels. If necessary, the dose of antidiabetic drugs should be adjusted during and after treatment with neuroleptic drugs. ② Glucocorticoids and teicoplanin (systemic and local routes: intra-articular, skin and rectal preparations): (with the exception of hydrocortisone as an alternative treatment in ADDISON's disease) Blood sugar levels will increase, sometimes accompanied by ketosis (decreased carbohydrate tolerance caused by glucocorticoids). Patients need to be warned and the importance of self-monitoring blood sugar needs to be emphasized, especially at the beginning of treatment. It is necessary to adjust the dose of drugs for treating diabetes during the use of glucocorticoids and after discontinuation of the drug. ③ Szlig;2 sympathomimetic drugs: hydroxyephedrine, salbutamol, and tributamol increase blood sugar levels due to their p2 agonist effects. The importance of self-monitoring blood sugar needs to be emphasized. Switch to insulin if necessary.

Its chemical name is: l_(3-azabicyclo【3.3.0】octyl)-3-p-toluenesulfonylurea.

1 The following drugs may increase the risk of hypoglycemia. (1) Concomitant use is prohibited: Miconazole (oral route, oral gel): Increases the hypoglycemic effect and may cause hypoglycemic symptoms, even coma. (2) Concomitant use is not recommended: ① Phenylbutazone (systemic route): Increases the hypoglycemic effect of sulfonylurea drugs [replaces their binding to plasma proteins and (or) reduces their clearance]. It is best to use an anti-inflammatory drug with few interactions. Otherwise, the patient should be warned and the importance of self-monitoring should be emphasized; when used with anti-inflammatory drugs, it is necessary to adjust the drug dosage during treatment and during the treatment interruption stage. ② Alcohol: Increases hypoglycemic reactions, especially chlorpropamide, glibenclamide, glipizide, and toluidine (by inhibiting compensatory reactions), and also increases the risk of hypoglycemic coma. Avoid consuming alcohol or taking medications containing alcohol. (3) Caution is required in combined use: ① SZL receptor blockers: All SZL receptor blockers can mask certain symptoms of hypoglycemia, such as palpitations and tachycardia. Most non-cardioselective szlig; receptor blockers increase the suddenness and severity of hypoglycemia. Patients should be warned and the importance of self-monitoring of blood glucose should be emphasized, especially at the beginning of treatment. ② Fluconazole: Increases the half-life of sulfonylurea drugs and the risk of hypoglycemia symptoms. Patients should be warned and the importance of self-monitoring of blood glucose should be emphasized, and the dose of sulfonylurea drugs should be adjusted when necessary during fluconazole treatment. ④ Angiotensin-converting enzyme inhibitors (generally referring to captopril and enalapril): The use of angiotensin-converting enzyme inhibitors will aggravate the hypoglycemic effect of sulfonylurea hypoglycemic drugs. Symptomatic hypoglycemia is very rare. One theory is that improved glucose tolerance helps reduce the need for insulin. The importance of self-monitoring of blood glucose should be emphasized. 2 The following drugs may cause increased blood sugar levels: (1) It is recommended not to use them in combination: ① Danazol: Diabetogenic effect. If this drug cannot be avoided, patients should be warned and the importance of self-monitoring of urine sugar and blood sugar should be emphasized. When using and stopping ILdanazol treatment, the dose of diabetes treatment drugs needs to be adjusted. (2) Combined use requires caution: ① Chlorpromazine (psychotropic agent): Treatment with high-dose chlorpromazine (daily chlorpromazine dose of 100 mg) will increase blood sugar levels (reduce insulin release). Inform patients and emphasize the need for self-monitoring of IIL glucose levels. If necessary, the dose of antidiabetic drugs should be adjusted during and after treatment with neuroleptic drugs. ② Glucocorticoids and teicoplanin (systemic and local routes: intra-articular, skin and rectal preparations): (with the exception of hydrocortisone as an alternative treatment in ADDISON's disease) Blood sugar levels will increase, sometimes accompanied by ketosis (decreased carbohydrate tolerance caused by glucocorticoids). Patients need to be warned and the importance of self-monitoring blood sugar needs to be emphasized, especially at the beginning of treatment. It is necessary to adjust the dose of drugs for treating diabetes during the use of glucocorticoids and after discontinuation of the drug. ③ Szlig;2 sympathomimetic drugs: hydroxyephedrine, salbutamol, and tributamol increase blood sugar levels due to their p2 agonist effects. The importance of self-monitoring blood sugar needs to be emphasized. Switch to insulin if necessary.

Gliclazide, its chemical name is: 1-(3-azabicyclo[3.3.0]oct-3-yl)-3-toluenesulfonylurea.

1. The following drugs may increase the risk of hypoglycemia. (1) Concomitant use is prohibited - Diclofenac (systemic route, oral gel): Increases the hypoglycemic effect and may cause hypoglycemic symptoms and even coma. (2) Concomitant use is not recommended - Phenylbutazone (systemic route): Increases the hypoglycemic effect of sulfonylurea drugs (replaces their binding to plasma proteins, or reduces their excretion). It is best to use a different anti-inflammatory agent, otherwise, warn the patient and emphasize the importance of self-monitoring: When used with anti-inflammatory agents, it is necessary to adjust the drug dosage during and after anti-inflammatory treatment. - Alcohol: Increases hypoglycemic reactions (by inhibiting compensatory reactions) and has the potential risk of hypoglycemic coma. Avoid alcohol or drugs containing alcohol. (3) Use with caution in combination The hypoglycemic effect may be enhanced. Hypoglycemia may occur in some cases when used with the following drugs. Other hypoglycemic drugs (insulin, acarbose, biguanides), beta-receptor blockers, fluconazole, angiotensin-converting enzyme inhibitors (captopril, enalapril), H2-receptor antagonists, MAOls, sulfonamides, nonsteroidal anti-inflammatory drugs. 2. The following drugs may cause blood sugar levels to increase (1) It is recommended not to use them together - Danazol: Diabetogenic effect. If the use of this drug cannot be avoided, the patient needs to be warned and the importance of self-monitoring urine sugar and blood sugar needs to be emphasized. The dose of diabetes medication needs to be adjusted when using and stopping danazol treatment. (2) Use with caution - Chlorpromazine (antipsychotic drug): Treatment with high doses of chlorpromazine (daily chlorpromazine dose of 100 mg) will increase blood sugar levels (reduce insulin release). The patient needs to be informed and the importance of self-monitoring blood sugar needs to be emphasized. The dose of diabetes medication needs to be adjusted during and after antipsychotic treatment. -Glucocorticoids (systemic and local routes: intra-articular, cutaneous and rectal preparations) and tebuconazole (corticotropin): Possible ketosis and increased blood glucose levels (decreased carbohydrate tolerance caused by adrenocortical hormones). Patients need to be informed and the importance of self-monitoring of blood glucose needs to be emphasized. The dose of diabetes medications needs to be adjusted during and after treatment with adrenocortical hormones. -Benzyl hydroxyephedrine, salbutamol, tributofol: (intravenous injection) Due to the beta-2 agonist effect, blood glucose levels are increased. The importance of self-monitoring of blood glucose needs to be emphasized. If necessary, switch to insulin. 3. Other issues to consider for combined medications -Anticoagulants (warfarin) In general use, sulfonylureas may cause potential anticoagulant effects. It may be necessary to consider adjusting the dose of the anticoagulant.